Criteria to qualify for study: Drug used in study:
  • R/R transfusion-independent lymphoma, newly diagnosed AML, or R/R myeloma, ECOG <2

HR 56

A phase 1a/1b dose escalation and expansion trial of TTI/-622 in patients with advanced relapsed or refractory Lymphoma or Myeloma

https://clinicaltrials.gov/ct2/results?cond=&term=NCT03530683

Criteria to qualify for study: Drug used in study:
  • Relapsed or refractory after at least 2 prior lines of therapy.

HR 59

Phase 1 open-label, multicenter study designed to evaluate the study, tolerability, pharmacokinetics, and preliminary activity of tiragolumab administered as a single agent or in combination with Daratumumab or Rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non Hodgkin lymphoma.

https://clinicaltrials.gov/ct2/results?cond=&term=NCT04045028

Criteria to qualify for study: Drug used in study:
  • R/R AML or MDS

HR 61

A Phase 1 Study of SEA-CD70 as monotherapy or in combination, in AML or MDS

https://clinicaltrials.gov/ct2/show/NCT04227847

Criteria to qualify for study: Drug used in study:
  • Received at least 1 prior line of therapy for AML or MDS; ECOG<2

HR 63

A Phase 1 study of NKX101, an activating chimeric receptor natural killer (ACRNK) cell therapy in subjects with hematological malignancies or dysplasia’s.

https://clinicaltrials.gov/ct2/show/NCT04623944

Criteria to qualify for study: Drug used in study:
  • ECOG <3; LVET >50%

HR 64

A phase 1 open label, multicenter, dose escalation study of PRT1419 in subjects with relapsed/refractory hematological malignancies.

https://clinicaltrials.gov/ct2/show/NCT04543305

Criteria to qualify for study: Drug used in study:
  • Natural Killer Cell (CYNK-0012) infusion in Adults with AML

AML 51

Newly diagnosed AML including MDS-transformed or treatment related in first or second CR

https://clinicaltrials.gov/ct2/show/NCT04310592

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AML, ECOG<=2

AML 54

Randomized, open label, 2 arm, multicenter, phase 3 study of Venetoclax and Azacitidine versus best supportive care as maintenance therapy of patients with Acute Myeloid Leukemia in first remission after conventional chemotherapy (VIALE-M)

https://clinicaltrials.gov/ct2/show/NCT04102020

Criteria to qualify for study: Drug used in study:
  • 2nd Morphological complete remission for AML; WT1 blasts

AML 56

A randomized, open-label study of the efficacy and safety of Galinpepimut-S (GPS) Maintenance monotherapy compared to Investigator’s choice of best available therapy in subjects with Acute Myeloid Leukemia who have achieved complete remission after second line of salvage therapy.

https://clinicaltrials.gov/ct2/show/NCT04229979

Criteria to qualify for study: Drug used in study:
  • AML, MDS, or ALAL

BMT 37

Phase 1 study of escalating single and multiple doses of Mana 312 (multi tumor associated antigen T cells) administered to adult subjects with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplant

https://clinicaltrials.gov/ct2/show/NCT04679194

Criteria to qualify for study: Drug used in study:
  • Relapsed or refractory AML; previously untreated AML not suitable for intensive induction.

RM 708

Phase ½ study of RTX – 240 as monotherapy and in combination with Pembrolizumab

https://clinicaltrials.gov/ct2/show/NCT04372706